Apremilast Efficacy Results Disappoint But May Be Enough For Commercial Success
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Celgene’s PDE-4 inhibitor met the primary endpoint in the first of two pivotal psoriasis trials, but analysts worried that the treatment effect was less than that seen in a Phase II study. Some analysts see a niche for apremilast in treatment-naïve patients before they move on to biologic therapy. Celgene aims to begin apremilast regulatory filings this autumn, first targeting psoriatic arthritis.
You may also be interested in...
Celgene Lays Out Catalysts For Strong 2013, Highlights Apremilast
Celgene reported strong sales for key products, led by Revlimid, during its year-end 2012 call. The biopharma affirmed 2013 guidance, detailing the key regulatory and commercial drivers that will power the global expansion of its hematology, oncology, and immunology franchises. In particular, it highlighted the commercial potential for apremilast.
Celgene Makes A Play For Inflammation & Immunology Stake With Apremilast
With a foundation established in oncology, Celgene is targeting new areas for growth; apremilast, for psoriasis and psoriatic arthritis, is key to the effort.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.